Keybanc Maintains Overweight on Alcon, Lowers Price Target to $84

Alcon: Keeping An Eye Out Here Amid Sales And Margin Momentum (NYSE:ALC)

Alcon: Keeping An Eye Out Here Amid Sales And Margin Momentum

Alcon Inc (ALC) Shares Surge 4.8% -- What GF Score of 74 Tells I

Alcon's Neurotech Acquisition Offers Significant Growth Potential, Needham Says

Needham Reiterates Buy on Alcon, Maintains $98 Price Target

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Alcon Acquires Neurotech Pharmaceuticals For $550M

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio.

Ryan Israel on Investing Beyond AI

BTIG Maintains Buy on Alcon, Lowers Price Target to $74

Intel downgraded, Marvell upgraded: Wall Street's top analyst calls

AeraHUB 26 NYC Brings the Decision-Centric Enterprise to Life

Alcon (SWX:ALC) Stock Trades Above Fair Value On Earnings Pressure